BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Billes SK, Greenway FL. Combination therapy with naltrexone and bupropion for obesity. Expert Opinion on Pharmacotherapy 2011;12:1813-26. [DOI: 10.1517/14656566.2011.591382] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
Number Citing Articles
1 Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res 2014;84:1-11. [PMID: 24754973 DOI: 10.1016/j.phrs.2014.04.004] [Cited by in Crossref: 69] [Cited by in F6Publishing: 60] [Article Influence: 8.6] [Reference Citation Analysis]
2 Boswell RG, Potenza MN, Grilo CM. The Neurobiology of Binge-eating Disorder Compared with Obesity: Implications for Differential Therapeutics. Clin Ther 2021;43:50-69. [PMID: 33257092 DOI: 10.1016/j.clinthera.2020.10.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 McGill AT. Past and future corollaries of theories on causes of metabolic syndrome and obesity related co-morbidities part 2: a composite unifying theory review of human-specific co-adaptations to brain energy consumption. Arch Public Health 2014;72:31. [PMID: 25708599 DOI: 10.1186/2049-3258-72-31] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
4 Murray E, Brouwer S, Mccutcheon R, Harmer CJ, Cowen PJ, Mccabe C. Opposing neural effects of naltrexone on food reward and aversion: implications for the treatment of obesity. Psychopharmacology 2014;231:4323-35. [DOI: 10.1007/s00213-014-3573-7] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
5 Saunders KH, Igel LI, Aronne LJ. An update on naltrexone/bupropion extended-release in the treatment of obesity. Expert Opinion on Pharmacotherapy 2016;17:2235-42. [DOI: 10.1080/14656566.2016.1244527] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
6 Caixàs A, Albert L, Capel I, Rigla M. Naltrexone sustained-release/bupropion sustained-release for the management of obesity: review of the data to date. Drug Des Devel Ther. 2014;8:1419-1427. [PMID: 25258511 DOI: 10.2147/dddt.s55587] [Cited by in Crossref: 44] [Cited by in F6Publishing: 21] [Article Influence: 5.5] [Reference Citation Analysis]
7 Adan RA. Mechanisms underlying current and future anti-obesity drugs. Trends Neurosci 2013;36:133-40. [PMID: 23312373 DOI: 10.1016/j.tins.2012.12.001] [Cited by in Crossref: 72] [Cited by in F6Publishing: 64] [Article Influence: 8.0] [Reference Citation Analysis]
8 Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clin Ther 2021;43:112-122.e1. [PMID: 33218742 DOI: 10.1016/j.clinthera.2020.10.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Stahl SM, Sy S, Maguire GA. How and when to treat the most common adverse effects of antipsychotics: Expert review from research to clinical practice. Acta Psychiatr Scand 2021;143:172-80. [PMID: 33306204 DOI: 10.1111/acps.13266] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
10 Charakida M, Finer N. Drug treatment of obesity in cardiovascular disease. Am J Cardiovasc Drugs. 2012;12:93-104. [PMID: 22292446 DOI: 10.2165/11599000-000000000-00000] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
11 Howland RH. Therapies for obesity and medication-associated weight gain. J Psychosoc Nurs Ment Health Serv 2013;51:13-6. [PMID: 23590816 DOI: 10.3928/02793695-20130411-01] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
12 Sweeting AN, Hocking SL, Markovic TP. Pharmacotherapy for the treatment of obesity. Molecular and Cellular Endocrinology 2015;418:173-83. [DOI: 10.1016/j.mce.2015.09.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
13 Imperatori C, Valenti EM, Della Marca G, Amoroso N, Massullo C, Carbone GA, Maestoso G, Quintiliani MI, Contardi A, Farina B. Coping food craving with neurofeedback. Evaluation of the usefulness of alpha/theta training in a non-clinical sample. International Journal of Psychophysiology 2017;112:89-97. [DOI: 10.1016/j.ijpsycho.2016.11.010] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
14 Gouni-Berthold I, Berthold HK. Current Options for the Pharmacotherapy of Obesity. Curr Pharm Des 2019;25:2019-32. [PMID: 31298150 DOI: 10.2174/1381612825666190708192630] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Oo WM, Mobasheri A, Hunter DJ. A narrative review of anti-obesity medications for obese patients with osteoarthritis. Expert Opin Pharmacother 2022. [PMID: 35855642 DOI: 10.1080/14656566.2022.2104636] [Reference Citation Analysis]
16 Rueda-clausen CF, Padwal RS, Sharma AM. New pharmacological approaches for obesity management. Nat Rev Endocrinol 2013;9:467-78. [DOI: 10.1038/nrendo.2013.113] [Cited by in Crossref: 37] [Cited by in F6Publishing: 30] [Article Influence: 4.1] [Reference Citation Analysis]
17 Reece AS, Hulse GK. Impact of lifetime opioid exposure on arterial stiffness and vascular age: cross-sectional and longitudinal studies in men and women. BMJ Open 2014;4:e004521. [PMID: 24889849 DOI: 10.1136/bmjopen-2013-004521] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 3.0] [Reference Citation Analysis]
18 Still CD, Wood GC, Chu X, Manney C, Strodel W, Petrick A, Gabrielsen J, Mirshahi T, Argyropoulos G, Seiler J, Yung M, Benotti P, Gerhard GS. Clinical factors associated with weight loss outcomes after Roux-en-Y gastric bypass surgery. Obesity (Silver Spring) 2014;22:888-94. [PMID: 23804287 DOI: 10.1002/oby.20529] [Cited by in Crossref: 92] [Cited by in F6Publishing: 85] [Article Influence: 11.5] [Reference Citation Analysis]
19 Chaijale NN, Aloyo VJ, Simansky KJ. The stereoisomer (+)-naloxone potentiates G-protein coupling and feeding associated with stimulation of mu opioid receptors in the parabrachial nucleus. J Psychopharmacol 2013;27:302-11. [DOI: 10.1177/0269881112472561] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]